Oppenheimer & CO Inc Aurinia Pharmaceuticals Inc. Transaction History

Oppenheimer & CO Inc

$6.42 Billion
Q3 2024

A detailed history of Oppenheimer & CO Inc transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 14,710 shares of AUPH stock, worth $119,739. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,710

Previous 14,710 -0.0%

Holding current value

$119,739

Previous $83,000 28.92%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$4.81 - $5.78 $2,405 - $2,890	-500 Reduced 3.29%	14,710 $83,000
Q1 2024 May 06, 2024	SELL	$4.93 - $9.31 $18,241 - $34,447	-3,700 Reduced 19.57%	15,210 $76,000
Q4 2023 Feb 13, 2024	BUY	$7.13 - $9.49 $71 - $94	10 Added 0.05%	18,910 $170,000
Q2 2023 Aug 02, 2023	SELL	$8.96 - $11.69 $22,400 - $29,225	-2,500 Reduced 11.68%	18,900 $182,000
Q1 2023 May 10, 2023	BUY	$5.94 - $11.27 $17,820 - $33,810	3,000 Added 16.3%	21,400 $234,000
Q4 2022 Feb 07, 2023	SELL	$4.11 - $8.14 $13,152 - $26,048	-3,200 Reduced 14.81%	18,400 $79,000
Q3 2022 Nov 14, 2022	SELL	$6.66 - $12.39 $13,320 - $24,780	-2,000 Reduced 8.47%	21,600 $162,000
Q2 2022 Aug 08, 2022	BUY	$8.95 - $12.8 $8,950 - $12,800	1,000 Added 4.42%	23,600 $237,000
Q1 2022 May 12, 2022	BUY	$10.05 - $22.48 $26,130 - $58,448	2,600 Added 13.0%	22,600 $280,000
Q4 2021 Feb 02, 2022	BUY	$17.78 - $33.08 $39,116 - $72,776	2,200 Added 12.36%	20,000 $457,000
Q3 2021 Nov 12, 2021	SELL	$10.93 - $23.55 $139,510 - $300,592	-12,764 Reduced 41.76%	17,800 $394,000
Q2 2021 Aug 03, 2021	BUY	$10.0 - $14.52 $2,740 - $3,978	274 Added 0.9%	30,564 $396,000
Q1 2021 May 10, 2021	BUY	$12.3 - $18.73 $372,567 - $567,331	30,290 New	30,290 $393,000

Others Institutions Holding AUPH

# of Institutions

209

Shares Held

58.2M

Call Options Held

1.14M

Put Options Held

1.51M

View Full List

About Aurinia Pharmaceuticals Inc.

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.16B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

More about AUPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.

Account

Oppenheimer & CO Inc Aurinia Pharmaceuticals Inc. Transaction History